Normal view MARC view ISBD view

Exploring the unintended consequences of misuse of wegovy and ozempic in weight management : a comprehensive review

By: Kute, Sarthak A .

Contributor(s): Chothave, Madhura S .

Publisher: Bhopal Innovare Academic Sciences Pvt Ltd 2024Edition: Vol.16(6).Description: 10-13p.Subject(s): PHARMACEUTICS

Online resources: Click here In: International journal of pharmacy and pharmaceutical scienceSummary: In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as promising options for weight management, offering not only glycemic control benefits but also significant reductions in body weight. Among these agents, Wegovy (semaglutide) and Ozempic (semaglutide) have gained attention for their efficacy in promoting weight loss, even in individuals without diabetes. However, the off-label use of these medications for weight management raises several questions and concerns regarding their safety, efficacy, and long-term effects. This comprehensive review aims to explore the complexities of GLP-1 agonists in weight management, focusing on their mechanism of action, clinical evidence, safety profile, dosing considerations, potential interactions, and future directions.

Tags from this library: No tags from this library for this title. Log in to add tags.

average rating: 0.0 (0 votes)

Holdings ( 1 )
Title notes
Comments ( 0 )
Images

Item type	Current location	Call number	Status	Date due	Barcode	Item holds
Articles Abstract Database	School of Pharmacy Archieval Section		Not for loan		2025-1368

Total holds: 0

Browsing School of Pharmacy Shelves , Shelving location: Archieval Section Close shelf browser

Previous	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	Next
Previous	Bioremediation of sanitary napkin by cellulose-degrading bacteria	Production and characterization of chitooligosaccharide hydrolysate prepared from chitosanase enzyme of marine isolates	Unlocking the therapeutic potential	Exploring the unintended consequences of misuse of wegovy and ozempic in weight management	Environmental impact and regulatory compliance: a comprehensive approach in managing institutional pharmaceutical waste	Regulatory perspective for gene therapy products in the USA, EU and Japan and future aspects	Advances in cocrystals of anticancer agents: formulation strategies and therapeutic implications	Next

In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as promising options for weight management, offering not only glycemic control benefits but also significant reductions in body weight. Among these agents, Wegovy (semaglutide) and Ozempic (semaglutide) have gained attention for their efficacy in promoting weight loss, even in individuals without diabetes. However, the off-label use of these medications for weight management raises several questions and concerns regarding their safety, efficacy, and long-term effects. This comprehensive review aims to explore the complexities of GLP-1 agonists in weight management, focusing on their mechanism of action, clinical evidence, safety profile, dosing considerations, potential interactions, and future directions.